Suppr超能文献

泛素系统、疾病与药物发现。

The ubiquitin system, disease, and drug discovery.

作者信息

Petroski Matthew D

机构信息

Rigel Pharmaceuticals, Inc, South San Francisco, CA, 94080, USA.

出版信息

BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S7. doi: 10.1186/1471-2091-9-S1-S7.

Abstract

The ubiquitin system of protein modification has emerged as a crucial mechanism involved in the regulation of a wide array of cellular processes. As our knowledge of the pathways in this system has grown, so have the ties between the protein ubiquitin and human disease. The power of the ubiquitin system for therapeutic benefit blossomed with the approval of the proteasome inhibitor Velcade in 2003 by the FDA. Current drug discovery activities in the ubiquitin system seek to (i) expand the development of new proteasome inhibitors with distinct mechanisms of action and improved bioavailability, and (ii) validate new targets. This review summarizes our current understanding of the role of the ubiquitin system in various human diseases ranging from cancer, viral infection and neurodegenerative disorders to muscle wasting, diabetes and inflammation. I provide an introduction to the ubiquitin system, highlight some emerging relationships between the ubiquitin system and disease, and discuss current and future efforts to harness aspects of this potentially powerful system for improving human health. PUBLICATION HISTORY : Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

摘要

蛋白质修饰的泛素系统已成为参与调控多种细胞过程的关键机制。随着我们对该系统中各途径的了解不断深入,蛋白质泛素与人类疾病之间的联系也日益紧密。2003年,蛋白酶体抑制剂万珂(Velcade)获美国食品药品监督管理局(FDA)批准,泛素系统在治疗方面的潜力得以彰显。目前,针对泛素系统的药物研发活动旨在:(i)拓展具有独特作用机制和更高生物利用度的新型蛋白酶体抑制剂的开发;(ii)验证新的靶点。本综述总结了我们目前对泛素系统在从癌症、病毒感染、神经退行性疾病到肌肉萎缩、糖尿病和炎症等各种人类疾病中所起作用的理解。我将介绍泛素系统,强调泛素系统与疾病之间一些新出现的关系,并讨论当前及未来利用这一潜在强大系统的各个方面来改善人类健康的努力。发表历史:转载自Current BioData的靶向蛋白质数据库(TPdb;http://www.targetedproteinsdb.com)。

相似文献

1
The ubiquitin system, disease, and drug discovery.泛素系统、疾病与药物发现。
BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S7. doi: 10.1186/1471-2091-9-S1-S7.
3
10
A patent review of the ubiquitin ligase system: 2015-2018.专利审查的泛素连接酶系统:2015-2018。
Expert Opin Ther Pat. 2018 Dec;28(12):919-937. doi: 10.1080/13543776.2018.1549229. Epub 2018 Nov 23.

引用本文的文献

2
Deubiquitinases and Cancer.去泛素化酶与癌症
J Pharm Bioallied Sci. 2024 Dec;16(Suppl 5):S4210-S4220. doi: 10.4103/jpbs.jpbs_517_24. Epub 2025 Jan 30.
4
Expanding the inhibitor space of the WWP1 and WWP2 HECT E3 ligases.拓展 WWPI 和 WWP2 HECT E3 连接酶的抑制剂空间。
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2394895. doi: 10.1080/14756366.2024.2394895. Epub 2024 Sep 2.
10
Protein homeostasis in the aged and diseased heart.衰老和患病心脏中的蛋白质稳态
J Cardiovasc Aging. 2023;3(2). doi: 10.20517/jca.2023.4. Epub 2023 Mar 7.

本文引用的文献

1
The UPS in diabetes and obesity.糖尿病和肥胖症中的泛素蛋白酶体系统
BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S6. doi: 10.1186/1471-2091-9-S1-S6.
2
Role of the UPS in Liddle syndrome.泛素蛋白酶体系统在利德尔综合征中的作用。
BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S5. doi: 10.1186/1471-2091-9-S1-S5.
3
HPV E6, E6AP and cervical cancer.人乳头瘤病毒E6、E6相关蛋白与宫颈癌
BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S4. doi: 10.1186/1471-2091-9-S1-S4.
4
Deubiquitylating enzymes and disease.去泛素化酶与疾病
BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S3. doi: 10.1186/1471-2091-9-S1-S3.
5
9
HECT E3s and human disease.HECT E3泛素连接酶与人类疾病
BMC Biochem. 2007 Nov 22;8 Suppl 1(Suppl 1):S6. doi: 10.1186/1471-2091-8-S1-S6.
10
Ubiquitin-mediated signalling and Paget's disease of bone.泛素介导的信号传导与骨佩吉特病
BMC Biochem. 2007 Nov 22;8 Suppl 1(Suppl 1):S5. doi: 10.1186/1471-2091-8-S1-S5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验